

ॐ Omkar Pharmachem Ltd.

Date: 30/05/2018

To,
B S E Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001

Sub: - Audited Financial Result under Regulation 33 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 for the Quarter and year ended on 31st March, 2018

Company Scrip Code: 532167

Dear Sir,

Pursuant to the provisions of Regulation 33 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015, please find enclosed herewith:

1. Audited Financial Results of the Company, for the Quarter and year ended on 31st March, 2018, for your kind perusal and reference.
2. Statement of Asset and Liability of the Company.
3. Audit report issued by the statutory auditor of the Company.
4. Declaration Under Regulation 33(3)(d) of SEBI (Listing Obligation And Disclosure Requirement) Regulation 2015.

The aforesaid result has been approved by the Board of Directors at their meeting held on 30th May, 2018.

This is for your information and record.

Thanking You,

Yours faithfully,
For **Omkar Pharmachem Limited**



(Anurag Sharma)
Managing Director
DIN-02289261

Add: A-727, Sarita Vihar, New Delhi-110076

Encl: a/a

ॐ Omkar Pharmachem Ltd.

Statement of Standalone Audited Financial Results for the Quarter and Year ended 31st March, 2018						
(Rs. in lakh except per share data)						
Sr. No	Particulars	Quarter Ended on			Financial Year ended on	
		31-03-2018 (audited)	31-12-2017 (unaudited)	31-03-2017 (audited)	31-03-2018 (audited)	31-03-2017 (audited)
	Part-I					
1	Income from operations					
	a)Net Sales/ Income from Operations	0.00	0.00	0.00	0.00	0.00
	b)Other Operating Income	0.00	0.00	0.00	0.00	0.00
		0.00	0.00	0.00	0.00	0.00
2	Other Income	0.00	0.00	0.00	0.00	0.55
3	Net Total income	0.00	0.00	0.00	0.00	0.55
4	Expenses					
	a) Cost of material consumed	0.00	0.00	0.00	0.00	0.00
	b) Purchase of Stock-in-trade	0.00	0.00	0.00	0.00	0.00
	c) Changes in Inventories of Finished Goods, WIP and Stock-in trade	0.00	0.00	0.00	0.00	0.00
	d) Employee benefits expenses	3.44	3.68	3.53	13.99	13.70
	e)Finance Costs	1.32	0.00	0.01	1.37	0.02
	f) Depreciation and Amortization Expenses	0.10	0.06	0.05	0.25	0.24
	g) Other Expenses	1.63	1.12	2.94	9.69	7.84
	Total Expenses	6.49	4.86	6.53	25.30	21.80
5	Profit(Loss) before before exceptional items and tax(3-4)	(6.49)	(4.86)	(6.53)	(25.30)	(21.25)
6	Exceptional items: Profit on sale of fixed assets	0.00	0.00	0.00	0.00	48.19
7	Profit(Loss) from before Tax(5+6)	(6.49)	(4.86)	(6.53)	(25.30)	26.94
8	Tax Expense	0.01	0.30	(0.29)	0.31	4.88
9	Profit(Loss) for the period (7-8)	(6.50)	(5.16)	(6.24)	(25.61)	22.06
10	Other Comprehensive Income (Expense)	0.00	0.00	0.00	0.00	0.00
11	Total Comprehensive Income for the period	(6.50)	(5.16)	(6.24)	(25.61)	22.06
12	Paid up Equity Share Capital (Face Value Rs. 10/-)	1008.37	1008.37	1008.37	1008.37	1008.37
13	Reserves excluding Revaluation Reserved as on 31st March	(96.26)	(70.65)	(70.65)	(96.26)	(70.65)
14	Earning Per Share(before & after extraordinary items)(of Rs. 10 each)(not annualised) Basic and diluted Rs.	(0.0645)	(0.0512)	(0.0619)	(0.2540)	0.2188



ॐ Omkar Pharmachem Ltd.


Statement of Assets and Liabilities		(Rs. in lakh)	
Sr. No	Particulars	As at 31-03-2018 (audited)	As at 31-03-2017 (audited)
	ASSETS		
	Non-current Assets		
	a) Property, plant and equipment	0.65	0.32
	b) Capital work-in-progress	0.00	0.00
	c) Goodwill on consolidation	0.00	0.00
	d) Other intangible assets	0.00	0.00
	e) Intangible assets under development	0.00	0.00
	f) Financial assets	0.00	0.00
	i) Investments		
	a) Investment in associate	0.00	0.00
	b) Investments in joint ventures	0.00	0.00
	c) Other Investments	930.00	930.00
	ii) Other Financial Assets	0.00	0.00
	g) Deferred tax assets (net)	0.02	0.03
	h) Other non current assets	0.18	0.18
	Total Non-current Assets	930.85	930.53
	Current Assets		
	a) Inventories	0.00	0.00
	b) Financial assets		
	i) Other Investments	0.00	0.00
	ii) Trade receivables	7.46	7.46
	iii) Cash and cash equivalents	2.02	5.12
	iv) Bank balances other than iii) above	0.00	0.00
	v) Other financial assets	0.00	0.00
	c) Other current assets	0.00	0.00
	Total Current Assets	9.48	12.58
	Total Assets	940.33	943.11
	EQUITY AND LIABILITIES		
	Equity		
	a) Equity share capital	1008.37	1008.37
	b) Other equity : Reserve and Surplus	-96.26	-70.65
	Equity attributable to the owners of the company	912.11	937.72
	Non-controlling interests	0.00	0
	Total Equity	912.11	937.72
	Non-current liabilities		
	Financial liabilities		
	a) Borrowings	0.00	0.00
	b) Provisions	0.00	0.00
	c) Deferred tax liabilities(Net)	0.00	0.00
	Total Non-current Liabilities	0.00	0.00
	Current Liabilities		
	a) Financial liabilities		
	i) Borrowings	24.18	0.00
	ii) Trade Payables	1.89	3.15
	iii) Other financial liabilities	1.43	1.55
	b) Provisions	0.44	0.57
	c) Other current liabilities	0.28	0.12
	Total-current Liabilities	28.22	5.39
	Total Liabilities	28.22	5.39
	Total Equity and Liabilities	940.33	943.11

Notes:

- The above results have been reviewed by the audit committee & approved by the Board of Directors at the respective meeting held on 30-05-2018
- Corresponding previous period figures are regrouped/rearranged wherever necessary, to make them comparable.
- The financial result for the Quarter and year ended on 31-03-2018 has been prepared in accordance with the IND-AS specified under section 133 of the companies Act and rules made thereunder.
- The IND-AS regarding segment reporting is not applicable to the company as there is no segment.
- Reserves includes reserves and surplus.
- There is no change in Net Profit /Loss of the company due to the transition from Indian GAAP to IND-AS. Hence reconciliation statement is not required.
- The figures of last quarter are the balancing figures between audited figures in respect of the full financial year and the published year-to-date figures upto the third quarter of the current financial year.

Date : 30-05-2018
Place: Ahmedabad

By order of the Board


Anurag Sharma
Managing Director
DIN-02289261
Add- A-727,Sarita Vihar
New Delhi-110076



To The Board of Directors,
Omkar Pharmachem Limited,
Ahmedabad

We have audited the quarterly financial results of Omkar Pharmachem Limited for the quarter ended 31st March, 2018 and the year to date results for the period 1st April, 2017 to 31st March, 2018, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25 / Ind AS 34), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (ii) give a true and fair view of the net profit/ loss and other financial information for the quarter ended 31st March, 2018 as well as the year to date results for the period from 1st April, 2017 to 31st March, 2018.

For Rajesh J. Shah & Associates
Chartered Accountants
ERN 108407W

(Rajesh J. Shah)
Partner

Mem. No. 040268

Place : Ahmedabad

Date : 30/05/2018



Date: 30/05/2018

To,
B S E Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001

Scrip Code: 532167

Sub: - Declaration under Regulation 33(3)(d) of the SEBI (Listing Obligation And Disclosure Requirement) Regulation 2015,

Ref- Annual Audited Financial Results for the Quarter and year ended on 31st March 2018

DECLARATION


I, Anurag Sharma, Managing Director of the **OMKAR PHARMACHEM LIMITED** (CIN:L24231GJ1995PLC025276) having its registered office at 501, Mahakant Building Opp V.S. Hospital Ashram Road Ellisbridge Ahmedabad-380006, Gujarat, hereby declare that, the Statutory Auditor of the Company i.e. **M/s. Rajesh J. Shah & Associates (FRN: 108407W and M. No- 040268)** have issued an Audited Report with unmodified opinion on Audited Financial Results of the Company for the quarter and year ended on 31st March, 2018.

This Declaration is given in Compliance of Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended by the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016, vide notification No. SEBI/LAD-NRO/GN/2016-17/001 dated May 25, 2016 and Circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016.

Kindly take this declaration on your Records.

Thanking you,

Yours faithfully,
For **Omkar Pharmachem Limited**



(Anurag Sharma)
Managing Director
DIN 02289261

Add: A-727, Sarita Vihar, New Delhi, 110076